Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Revenue of Rocket Pharmaceuticals, Inc. (RCKT)
Revenue in 2023 (TTM): $
According to Rocket Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Rocket Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-7,098,000 | $-236,622,000 | $-245,595,000 | $-245,595,000 |
| 2022 | $ | $-6,266,000 | $-213,688,000 | $-221,863,000 | $-219,383,000 |
| 2021 | $ | $-5,373,000 | $-161,719,000 | $-169,069,000 | $-169,585,000 |
| 2020 | $ | $-1,145,000 | $-131,588,000 | $-139,700,000 | $-146,667,000 |
| 2019 | $ | $-426,000 | $-71,136,000 | $-77,270,000 | $-83,228,000 |
| 2018 | $ | $-330,000 | $-71,156,000 | $-74,518,000 | $-74,518,000 |
| 2017 | $ | $-204,000 | $-26,737,000 | $-29,497,000 | $-29,497,000 |
| 2016 | $ | $-169,000 | $-41,267,000 | $-42,854,000 | $-42,854,000 |
| 2015 | $ | $-45,000 | $-20,262,000 | $-67,982,000 | $-67,982,000 |
| 2014 | $ | $ | $-7,704,000 | $-9,531,000 | $-9,531,000 |
| 2013 | $ | $ | $-6,732,000 | $-7,616,000 | $-7,616,000 |
| 2012 | $ | $ | $-5,836,000 | $-6,058,000 | $-6,058,000 |